WO2010025410A3 - Screening method for identifying patients at risk of adverse hepatologic events - Google Patents

Screening method for identifying patients at risk of adverse hepatologic events Download PDF

Info

Publication number
WO2010025410A3
WO2010025410A3 PCT/US2009/055430 US2009055430W WO2010025410A3 WO 2010025410 A3 WO2010025410 A3 WO 2010025410A3 US 2009055430 W US2009055430 W US 2009055430W WO 2010025410 A3 WO2010025410 A3 WO 2010025410A3
Authority
WO
WIPO (PCT)
Prior art keywords
levels
identifying patients
risk
events
apolipoprotein
Prior art date
Application number
PCT/US2009/055430
Other languages
French (fr)
Other versions
WO2010025410A2 (en
Inventor
Russell Medford
Kenneth M. Borow
Hilda Maibach
Original Assignee
Salutria Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salutria Pharmaceuticals, Llc filed Critical Salutria Pharmaceuticals, Llc
Priority to CN2009801437323A priority Critical patent/CN102257389A/en
Priority to EP09810686A priority patent/EP2342569A4/en
Priority to CA2735582A priority patent/CA2735582A1/en
Priority to JP2011525253A priority patent/JP2012501454A/en
Publication of WO2010025410A2 publication Critical patent/WO2010025410A2/en
Publication of WO2010025410A3 publication Critical patent/WO2010025410A3/en
Priority to US13/036,510 priority patent/US20110245340A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Abstract

This present invention provides methods and kits for identifying patients at risk of suffering from a drug induced liver injury, particularly for an antioxidant drug, or for identifying patients who are suffering from early stages of a liver disorder by assessing the levels of apolipoprotein in a sample of the patient and comparing that to a reference value. The reference value is predetermined by identifying a population sample and determining an upper limit of normal value. This value is then used as a reference point for comparison of apolipoprotein levels from patient samples. In one embodiment, apolipoprotein levels are combined with ATL and/or total bilirubin levels for predicting liver damage, hepatotoxicity or hepatic events after drug administration.
PCT/US2009/055430 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events WO2010025410A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2009801437323A CN102257389A (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events
EP09810686A EP2342569A4 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events
CA2735582A CA2735582A1 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events
JP2011525253A JP2012501454A (en) 2008-08-28 2009-08-28 Screening methods to identify patients at risk for hepatologic adverse events
US13/036,510 US20110245340A1 (en) 2009-08-28 2011-02-28 Screening Method for Identifying Patients at Risk of Adverse Hepatologic Events

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9268608P 2008-08-28 2008-08-28
US61/092,686 2008-08-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/036,510 Continuation US20110245340A1 (en) 2009-08-28 2011-02-28 Screening Method for Identifying Patients at Risk of Adverse Hepatologic Events

Publications (2)

Publication Number Publication Date
WO2010025410A2 WO2010025410A2 (en) 2010-03-04
WO2010025410A3 true WO2010025410A3 (en) 2010-07-01

Family

ID=41722327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/055430 WO2010025410A2 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events

Country Status (5)

Country Link
EP (1) EP2342569A4 (en)
JP (1) JP2012501454A (en)
CN (1) CN102257389A (en)
CA (1) CA2735582A1 (en)
WO (1) WO2010025410A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585245C2 (en) * 2010-12-30 2016-05-27 Мухаммед Маджид Hepatoprotective action of garcinol
WO2012122024A2 (en) * 2011-03-04 2012-09-13 Russell Medford Screening method for identifying patients at risk of drug induced liver injury
CN103376323A (en) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 Application of apolipoprotein C-III as marker of obesity-diabetes
CN103063848B (en) * 2012-12-26 2015-06-03 潍坊三维生物工程集团有限公司 Kit for determination of apolipoprotein C2 by using immunoturbidimetry
WO2018109004A1 (en) * 2016-12-14 2018-06-21 Roche Diagnostics Gmbh Determination of interferents in a sample
EP3373012A1 (en) 2017-03-07 2018-09-12 Biopredictive Method of diagnosis of drug induced liver injury
CN110780071A (en) * 2019-11-11 2020-02-11 彭涛 Hepatitis B-related hepatocellular carcinoma prognosis detection kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935935A (en) * 1993-06-10 1999-08-10 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
US20070178438A1 (en) * 2003-05-23 2007-08-02 The Johns Hopkins University Apolipoprotein c-1 induced apoptosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500375A (en) 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
WO2000055635A1 (en) * 1999-03-16 2000-09-21 Serex Inc. Method and device for detection of apo a, apo b and the ratio thereof in saliva
JP2004123716A (en) * 2002-08-06 2004-04-22 Mitsubishi Pharma Corp Medicine for preventing and/or treating hepatic disorder caused by chemical substance
AU2003296085A1 (en) * 2002-12-24 2004-07-22 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
FR2870348B1 (en) * 2004-05-14 2010-08-27 Univ Angers METHOD FOR DIAGNOSING THE PRESENCE AND / OR SEVERITY OF A HEPATHIC PATHOLOGY IN A SUBJECT
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
US7856319B2 (en) * 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935935A (en) * 1993-06-10 1999-08-10 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US20070178438A1 (en) * 2003-05-23 2007-08-02 The Johns Hopkins University Apolipoprotein c-1 induced apoptosis
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2342569A4 *

Also Published As

Publication number Publication date
EP2342569A4 (en) 2012-07-04
CN102257389A (en) 2011-11-23
CA2735582A1 (en) 2010-03-04
WO2010025410A2 (en) 2010-03-04
EP2342569A2 (en) 2011-07-13
JP2012501454A (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2010025410A3 (en) Screening method for identifying patients at risk of adverse hepatologic events
Petta et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study
Farfel-Becker et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration
WO2009137015A3 (en) Biomarkers of ionizing radiation
Sverrild et al. Airway responsiveness to mannitol in asthma is associated with chymase‐positive mast cells and eosinophilic airway inflammation
Lee et al. Nuclear factor‐erythroid 2‐related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice
MX2018012580A (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia.
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
Fernandes et al. Sex differences in renal inflammation and injury in high-fat diet–fed Dahl salt-sensitive rats
Yao et al. Enhanced brain levels of 8, 12-iso-iPF2α-VI differentiate AD from frontotemporal dementia
Nakajima et al. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non‐alcoholic fatty liver disease: comparison with telomere‐specific quantitative FISH and p21 immunohistochemistry
CA2735578C (en) Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
WO2008097773A8 (en) Methods and devices for diagnosis of appendicitis
WO2012018535A3 (en) Wellness panel
MY150648A (en) Hla alleles associated with adverse drug reactions and methods for detecting such
WO2014179424A3 (en) Lipidomic biomarkers
WO2005078624A3 (en) A method of recruiting patients for a clinical study
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2005113797A3 (en) METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
Hu et al. Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver
WO2013036754A3 (en) Methods and compositions for diagnosis of ovarian cancer
WO2010054195A3 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP2415877A3 (en) Means and methods for diagnosing pancreatic cancer
WO2009141352A3 (en) Risk analysis in patients with and without metabolic syndrome
WO2007126901A3 (en) Apparatus and method for predicting disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980143732.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09810686

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011525253

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2735582

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009810686

Country of ref document: EP